Skip to main content
. 2022 Aug 12;17:384. doi: 10.1186/s13018-022-03276-1

Table 2.

Results of cortical bone morphometrical analysis for the nonoperated side

Sham C R VD R + VD
graphic file with name 13018_2022_3276_Figg_HTML.gif graphic file with name 13018_2022_3276_Figh_HTML.gif graphic file with name 13018_2022_3276_Figi_HTML.gif graphic file with name 13018_2022_3276_Figj_HTML.gif graphic file with name 13018_2022_3276_Figk_HTML.gif
BV of cortical bone (mm3) 4.65 ± 0.46 4.87 ± 0.25 5.05 ± 0.26 4.65 ± 0.34 5.15 ± 0.39
Cr. Ar (mm2) 5.68 ± 0.56 5.96 ± 0.30 6.18 ± 0.32 5.69 ± 0.42 6.29 ± 0.48
Cr. Th (mm) 0.36 ± 0.04 0.36 ± 0.02 0.39 ± 0.03 0.34 ± 0.03 0.38 ± 0.04

Sham, sham group; C, control group; R, romosozumab group; VD, active vitamin D3 group; and R + VD, romosozumab + active vitamin D3 group. Cr. Ar, cortical bone area; Cr. Th, cortical bone thickness. All parameters showed a greater increase in the R and R + VD groups than in the C group, but no significant differences were observed in BV, area, and thickness of the cortical bone between the groups